{
  "id": "osteoporosis",
  "title": "Osteoporosis",
  "lang": "en",
  "source_lang": "en",
  "summary": "A systemic skeletal disease in which reduced bone mass and deteriorated bone microarchitecture make bones fragile and prone to fracture.",
  "category": "health",
  "subcategory": "diseases",
  "type": "concept",
  "aliases": [
    "Bone thinning disease",
    "Porous bone disease"
  ],
  "generated_at": "2026-10-10",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/osteoporosis/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/osteoporosis/",
      "json": "https://aiwiki.page/zh/osteoporosis.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "Osteoporosis is a systemic skeletal disease in which bone mass and bone quality decline until bones become fragile and can fracture from minor trauma, such as a fall from standing height. The condition develops through an imbalance in bone cell activity, in which resorption by hormone-regulated osteoclasts outpaces formation, and it is usually silent until a fracture occurs. Because the skeleton is a living tissue, bone strength depends on homeostatic remodeling, on hormones such as estrogen and parathyroid hormone, and on nutritional inputs such as calcium and vitamin D. Osteoporosis is common among older women after menopause and increasingly recognized in men, and it is a major cause of disability and mortality in older adults, which makes it an important topic in public health and epidemiology.\n\nThis entry explains how the disease is defined and what happens to bone in it, then describes its causes, types, and risk factors, and the epidemiology and clinical course of its fractures. It then covers diagnosis through bone mineral density and fracture-risk tools, the evidence for screening and for non-drug prevention, and the main classes of pharmacological treatment, including antiresorptive and bone-forming agents. Special populations, the history of research and diagnostic criteria, health-policy and economic aspects, and unresolved controversies close the entry."
    },
    {
      "heading": "Definition and clinical significance",
      "text": "Osteoporosis is a systemic skeletal disease in which reduced bone mass and deterioration of bone microarchitecture compromise strength and increase susceptibility to fracture. It affects the skeleton as a whole, although the degree of bone loss and the likelihood of fracture vary between sites. The vertebrae, hip, and distal forearm near the wrist are characteristic fracture locations; the proximal humerus, pelvis, and ribs may also be affected. Its defining clinical consequence is skeletal fragility rather than a particular symptom or an isolated abnormal laboratory result. (niams.nih.gov)\n\nThe operational definition associated with the World Health Organization uses bone mineral density (BMD), expressed as a T-score: the number of standard deviations by which measured BMD differs from the mean in a young-adult reference population. A T-score of \\(-2.5\\) or lower defines densitometric osteoporosis. The international reference standard uses the femoral neck; the International Society for Clinical Densitometry’s 2023 positions also recognize measurements at the lumbar spine or total hip for diagnosis in postmenopausal women and men aged 50 years or older. Osteopenia, also called low bone mass, denotes \\(-2.5 < T < -1.0\\), whereas \\(T \\geq -1.0\\) falls within the normal densitometric category. These categories describe density, not an abrupt biological boundary: fracture risk increases progressively as BMD declines, and osteopenia does not necessarily imply low fracture risk. The adult T-score classification is not applied unchanged to children or younger adults. (iscd.org)\n\nA fragility fracture is a fracture resulting from low-energy trauma, conventionally a fall from standing height or less, that would not ordinarily break healthy bone. Vertebral fractures may also occur during ordinary activities such as bending or lifting, or even coughing. Fragility fracture and densitometric osteoporosis are related but not interchangeable concepts: fractures can occur in people whose T-scores remain above \\(-2.5\\). In older adults, a low-trauma hip or vertebral fracture can establish a clinical diagnosis of osteoporosis regardless of BMD, provided that another explanation for skeletal fragility has been excluded. The Bone Health and Osteoporosis Foundation’s 2022 clinician’s guide accordingly recognizes hip or vertebral fracture as clinically significant regardless of the density measurement. (who.int)\n\nBone quantity and bone quality make distinct contributions to strength. BMD measures mineral content relative to the size of the measured bone region, but it does not fully describe the arrangement or material properties of bone tissue. Quality includes the connectivity of the internal trabecular network, cortical structure, mineralization, the properties of the collagen matrix, and the rate of tissue turnover. Loss of structural connections or changes in tissue renewal can therefore weaken bone beyond what a density value alone indicates. The 2004 United States Surgeon General’s report emphasized that bone shape and architecture are at least as important as mass in providing mechanical strength. (ncbi.nlm.nih.gov)\n\nOsteoporosis is described as “silent” because declining bone mass usually produces no recognizable symptoms before a fracture. A broken bone is consequently often the event that first brings the disease to clinical attention, although density testing can identify it beforehand. Silence can persist even after vertebral fractures: many remain undiagnosed, while others produce back pain, loss of height, or a progressively stooped posture. The clinical significance extends beyond the initial break to impaired mobility, disability, and reduced quality of life; hip and vertebral fractures are particularly serious manifestations. (niams.nih.gov)"
    },
    {
      "heading": "Bone structure and remodeling",
      "text": "Cortical and trabecular bone are two arrangements of the same mineralized tissue. Cortical bone forms the dense outer shell of skeletal structures and accounts for approximately 80% of adult skeletal mass; its thick walls, particularly in long-bone shafts, resist bending and twisting. Trabecular, or cancellous, bone forms an internal network of plates and rods, especially in vertebral bodies and the ends of long bones. This network supports loads while enclosing spaces occupied by bone marrow. Trabecular bone has more exposed surface relative to its volume and undergoes faster turnover than cortical bone. Both compartments contribute to strength: the cortical shell provides structural rigidity, while the trabecular network distributes forces through the bone’s interior. (ncbi.nlm.nih.gov)\n\nBone remodeling renews existing tissue through the coordinated activity of small groups of cells called basic multicellular units. It differs from bone modeling, in which formation and resorption occur at separate locations, changing bone size or shape during growth and adaptation. Remodeling follows an activation–resorption–reversal–formation sequence. During activation, local signals associated with mechanical loading or microscopic damage recruit osteoclast precursors, which fuse into multinucleated osteoclasts. These cells attach to bone and remove mineral and organic matrix. In trabecular bone, they excavate shallow cavities on exposed surfaces; within cortical bone, they form “cutting cones” that tunnel through existing tissue. During reversal, cells of the osteoblast lineage occupy the resorbed surface and prepare it for new matrix deposition. (ncbi.nlm.nih.gov)\n\nResorption depends on acid secretion, which dissolves mineral, and enzymes that digest the organic matrix. It is followed by formation, carried out by osteoblasts. These cells produce osteoid, an initially unmineralized matrix rich in type I collagen, which subsequently matures and mineralizes. In cortical remodeling, osteoblasts deposit concentric layers around a residual central channel containing blood vessels, producing a new osteon. Formation is slower than removal: resorption generally occupies days to weeks, whereas replacement can require several months. The interval between excavation and complete refilling therefore leaves a temporary cavity, even when the final amount of replacement bone matches the amount removed. (ncbi.nlm.nih.gov)\n\nCoupling describes the communication that links resorption to subsequent formation at the same site. Osteoclast activity releases growth factors stored in the matrix, helping recruit and differentiate osteoblast precursors; communication between bone cells provides additional local regulation. In a balanced remodeling unit, newly formed bone approximately replaces the volume previously resorbed. Turnover rate and bone balance are therefore distinct: frequent remodeling does not necessarily reduce bone mass if each cavity is adequately refilled. Conversely, a small replacement deficit repeated across many remodeling units produces cumulative loss. Remodeling also repairs microscopic damage and helps maintain skeletal strength in response to mechanical forces. (ncbi.nlm.nih.gov)\n\nBone accumulation during childhood and adolescence establishes the skeletal reserve available in later life. Peak bone mass is generally reached during the twenties, although its timing varies by skeletal site and sex; cessation of longitudinal growth does not mean that bone mineral accumulation has ended. In young adulthood, formation and resorption can remain approximately balanced. With aging, resorption increasingly exceeds replacement, gradually reducing that reserve. At the structural level, incomplete replacement can increase cortical porosity and diminish the trabecular framework. Bone loss commonly accelerates in women after menopause, whereas its progression is generally slower in men; the hormonal and cellular mechanisms underlying these changes are distinct from the normal remodeling sequence itself. (ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Pathophysiology and mechanisms of bone loss",
      "text": "Estrogen deficiency after menopause increases the recruitment, activity, and survival of osteoclasts, the cells responsible for bone resorption. Estrogen normally restrains osteoclast formation and promotes their apoptosis; its withdrawal therefore increases the number of active resorption sites. Bone formation also increases through coupling between resorption and formation, but does not fully replace the removed tissue. Repeated remodeling with a negative balance thins and perforates trabeculae and increases cortical porosity. The resulting architectural deterioration is not simply a reduction in mineral concentration: the loss of connections between trabeculae compromises the skeleton’s mechanical integrity. (jci.org)\n\nA central mediator is the RANK–RANKL–osteoprotegerin pathway. RANK ligand (RANKL), produced by osteocytes and other osteoblast-lineage cells, binds RANK on osteoclast precursors. Together with macrophage colony-stimulating factor, this signaling promotes precursor differentiation, fusion, and survival, while also activating mature osteoclasts. Osteoprotegerin is a soluble decoy receptor that binds RANKL and prevents it from activating RANK. Estrogen deficiency shifts local signaling toward osteoclast formation through changes in RANKL availability and inflammatory mediators. In a 2003 human study, Ghada Eghbali-Fatourechi and colleagues found two- to threefold higher surface RANKL expression on bone marrow stromal cells, T lymphocytes, and B lymphocytes in untreated early postmenopausal women than in premenopausal or estrogen-treated postmenopausal women. Expression correlated with biochemical markers of bone resorption. (jci.org)\n\nAging also reduces the capacity of osteoblasts to replenish bone. Reduced progenitor proliferation, oxidative stress, and altered growth-factor signaling limit the supply and function of matrix-producing cells. Wnt–β-catenin signaling supports osteoblast development; experimental work published in 2013 showed that FOXO transcription factors can suppress this pathway in osteoblast progenitors, reducing their proliferation and bone formation in mice. Cellular senescence provides another link between aging and remodeling imbalance: senescent cells stop dividing and can release inflammatory factors that affect neighboring cells. In a 2020 mouse study, deleting RANKL specifically from osteocytes prevented age-related cortical bone loss; control animals developed declining spinal bone mineral density from approximately 20 months and femoral density from 24 months. These experiments identify mechanisms of skeletal aging without establishing identical timing or effect sizes in humans. (jci.org)\n\nCalcium homeostasis links the skeleton to the intestine, kidneys, and parathyroid glands. A fall in circulating ionized calcium stimulates parathyroid hormone (PTH), which increases renal calcium retention and production of calcitriol, the active form of vitamin D. Calcitriol promotes intestinal absorption of calcium and phosphate, providing substrates for bone mineralization. Inadequate calcium absorption or vitamin D deficiency can produce secondary hyperparathyroidism: sustained PTH elevation increases osteoclast-mediated resorption indirectly through osteoblast-lineage signaling, helping preserve blood calcium at the expense of skeletal stores. Consequently, normal serum calcium does not exclude substantial bone loss. Severe vitamin D deficiency can additionally impair mineralization, producing osteomalacia, a distinct disorder that may coexist with osteoporosis. PTH action depends on exposure pattern: sustained elevation favors resorption, whereas intermittent exposure can stimulate formation. (ncbi.nlm.nih.gov)\n\nThe immune system contributes through cytokines including tumor necrosis factor α (TNF-α), interleukin-1, and interleukin-6. TNF-α amplifies RANKL-dependent osteoclast formation and can inhibit osteoblast differentiation; interleukin-1 increases osteoclast activity and survival. Estrogen withdrawal removes part of the restraint on these signals. In 2000, Simone Cenci and colleagues showed that ovariectomy increased T-cell production of TNF-α in mice, whereas T-cell-deficient animals in that experimental model did not develop the corresponding increase in resorption or bone loss. This illustrates how immune-cell activity can amplify a hormonal disturbance within the marrow environment, rather than bone loss arising solely from direct hormone effects on bone cells. (jci.org)"
    },
    {
      "heading": "Types of osteoporosis",
      "text": "Osteoporosis is classified by cause into primary and secondary forms. Primary osteoporosis includes postmenopausal and age-related disease, as well as uncommon idiopathic forms in younger people. Secondary osteoporosis is attributable to an identifiable disease, medication, or other exposure that impairs skeletal strength. These categories are not mutually exclusive: an older adult may have age-related bone loss compounded by glucocorticoid treatment, malabsorption, or an endocrine disorder. Consequently, age or menopausal status alone does not establish that osteoporosis is exclusively primary. (ncbi.nlm.nih.gov)\n\nPostmenopausal osteoporosis is associated principally with the decline in estrogen around menopause, which increases bone resorption relative to formation. The accelerated phase particularly affects trabecular bone and contributes to vertebral and distal forearm fractures. Age-related osteoporosis, traditionally called senile osteoporosis, affects both women and men and involves progressive deterioration of cortical and trabecular bone, with impaired bone formation contributing to skeletal loss. B. Lawrence Riggs and L. Joseph Melton proposed the historical distinction between type I, or postmenopausal, and type II, or age-related, osteoporosis in 1983. Type I was associated especially with the first 15–20 years after menopause. These labels describe overlapping patterns rather than sharply separated diseases: their subsequent 1998 model emphasized that estrogen deficiency also contributes to later-life bone loss in women and aging men. (pubmed.ncbi.nlm.nih.gov)\n\nSecondary osteoporosis encompasses several mechanistically distinct conditions. Systemic glucocorticoids, including prednisone, impair bone formation and alter calcium and sex-hormone physiology; the underlying inflammatory disease can add further skeletal damage. Other medication-related forms occur with aromatase inhibitors used in breast cancer and androgen-deprivation treatment for prostate cancer. Endocrine causes include hyperthyroidism, hyperparathyroidism, Cushing syndrome, and hypogonadism. Gastrointestinal disorders such as celiac disease can reduce nutrient absorption, while rheumatoid arthritis combines inflammatory effects with reduced mobility and, in some patients, glucocorticoid exposure. Chronic kidney disease requires particular diagnostic care because renal osteodystrophy can coexist with osteoporosis and involves different abnormalities of bone turnover and mineralization. (endocrine.org)\n\nIn children and adolescents, osteoporosis is usually secondary to chronic illness, medication exposure, nutritional disturbance, or prolonged immobility. Idiopathic juvenile osteoporosis is a rare diagnosis made when no underlying cause is identified; it typically begins shortly before puberty in otherwise healthy children. Fractures may cause limping or pain in the back, hips, and feet. Bone health frequently improves during subsequent growth, although severe disease can leave permanent deformities. Pediatric classification cannot simply reproduce adult densitometric criteria: the International Society for Clinical Densitometry’s 2019 positions specify that low bone density alone does not establish childhood osteoporosis, and that vertebral compression fractures without high-energy trauma or local disease can establish the diagnosis. (niams.nih.gov)\n\nIdiopathic osteoporosis in young adults likewise denotes skeletal fragility without an identified secondary cause, rather than a single established mechanism. Some apparently idiopathic cases have a genetic basis, including variants affecting collagen or Wnt signaling, which regulates bone formation. A sequencing study published in 2017 examined 123 selected adults diagnosed before age 55 with low bone density. Eleven carried rare or novel variants in COL1A2, PLS3, WNT1, or DKK1. These findings illustrate the overlap between idiopathic osteoporosis and inherited skeletal fragility, including osteogenesis imperfecta, whose milder forms may lack conspicuous extraskeletal signs. The study’s selected cohort does not establish the prevalence of such variants in the general population. (pmc.ncbi.nlm.nih.gov)\n\nEtiologic classification directs the diagnostic work-up and modifies treatment planning. Evaluation includes medication and disease histories, nutritional assessment, and laboratory investigation for potentially reversible contributors; findings may prompt testing for thyroid disease, malabsorption, hypogonadism, or abnormal calcium metabolism. Treating an underlying disorder does not necessarily eliminate the need for fracture-prevention medication. Glucocorticoid-induced disease illustrates this distinction: the American College of Rheumatology’s 2022 guideline, published in 2023, addresses exposure of at least 2.5 mg/day prednisone-equivalent for more than three months and calls for early fracture-risk assessment, with pharmacological treatment determined by risk category. In younger patients, growth, reproductive circumstances, inherited disease, and the possibility of spontaneous recovery make management different from routine postmenopausal care. (ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Risk factors",
      "text": "Increasing age and female sex are major non-modifiable risk factors. Aging combines progressive bone loss with declining muscle strength and greater susceptibility to falls; age also predicts fracture independently of bone mineral density (BMD). Women generally have smaller bones and lower peak bone mass than men, and estrogen loss at menopause accelerates bone loss. Premature menopause and prolonged absence of menstruation increase risk by extending exposure to estrogen deficiency. In men, hypogonadism is an important risk factor. Population differences also occur: in the United States, osteoporosis is more common among non-Hispanic White and Asian women than among African American and Hispanic women, although all groups remain susceptible. These population associations do not determine an individual’s risk. (niams.nih.gov)\n\nFamily history reflects inherited influences on skeletal development as well as shared environments. A parental hip fracture predicts fracture risk largely independently of the offspring’s BMD. Genetic variation contributes to the amount of bone accumulated during growth: a 1999 study by S. François and colleagues involving 175 mother–daughter pairs estimated lumbar-spine BMD heritability at 53%, with a 95% confidence interval of 28.5–77.6%. Heritability describes variation within the studied population, not the proportion of an individual’s bone density attributable to inheritance. Small skeletal size is largely constitutional, whereas low body weight can also result from modifiable nutritional factors or illness. Low body mass index is particularly associated with hip fracture; its association with other fractures is substantially weakened after adjustment for BMD. (pubmed.ncbi.nlm.nih.gov)\n\nSmoking, chronic heavy alcohol consumption, inadequate nutrition, and physical inactivity are potentially modifiable exposures. Smoking-associated fracture risk is only partly explained by lower BMD. The 2024 National Osteoporosis Guideline Group guideline identifies a dose-dependent increase in fracture risk at alcohol consumption of three or more units daily. Diets deficient in calcium and vitamin D can compromise bone maintenance; vitamin D supports intestinal calcium absorption. Inadequate energy or protein intake and excessive dieting can accompany low body weight. Prolonged inactivity contributes to bone loss and physical deconditioning, thereby affecting both skeletal strength and the likelihood of falling. (nogg.org.uk)\n\nLong-term systemic glucocorticoid exposure, including prednisone, is an important medication-related risk. Bone loss and increased fracture risk develop rapidly after treatment begins, rise with dose, and are not explained by BMD alone. Other relevant drugs include aromatase inhibitors used for breast cancer and androgen-deprivation therapy used for prostate cancer, which reduce protective sex-hormone signaling. Medical conditions associated with skeletal fragility include hyperthyroidism, hypogonadism, chronic malabsorption, and rheumatoid arthritis. Rheumatoid arthritis confers risk independently of both BMD and glucocorticoid use. Both forms of diabetes mellitus increase fracture risk; notably, type 2 diabetes can do so despite normal or increased BMD. (nogg.org.uk)\n\nA previous fracture is a strong marker of subsequent fracture risk: risk is approximately doubled after a prior fracture, partly independently of BMD. Falls create an additional pathway to fracture without necessarily accelerating bone loss. Muscle weakness, impaired balance or vision, gait disorders, dementia, and sedating medications can increase fall exposure. Frailty combines diminished physical reserve with overlapping problems such as weakness, poor mobility, and undernutrition. Consequently, people with similar BMD can have different fracture risks because their likelihood of falling differs. (nogg.org.uk)"
    },
    {
      "heading": "Epidemiology and global burden",
      "text": "Global estimates of osteoporosis prevalence depend strongly on the age groups sampled, skeletal measurement sites, and diagnostic reference populations. A 2021 meta-analysis by Nader Salari and colleagues, incorporating 86 studies, estimated a pooled prevalence of 18.3% (95% confidence interval, 16.2–20.7%), with estimates of 23.1% in women and 11.7% in men. These figures describe the populations included in the studies rather than a directly measured proportion of the entire world population: participants ranged from 15 to 105 years, and statistical heterogeneity was substantial. A separate 2022 meta-analysis of 108 population-based studies using World Health Organization diagnostic criteria estimated prevalence at 19.7%, with regional estimates ranging from 8.0% in Oceania to 26.9% in Africa. Differences in sampling and sparse evidence in some regions limit straightforward comparisons between continents. (pmc.ncbi.nlm.nih.gov)\n\nNational surveys provide more clearly defined population estimates. In the United States, the 2017–2018 National Health and Nutrition Examination Survey found an age-adjusted prevalence of osteoporosis at the femoral neck, lumbar spine, or both of 12.6% among noninstitutionalized adults aged 50 years or older: 19.6% in women and 4.4% in men. Among women, prevalence was 13.1% at ages 50–64 and 27.1% at age 65 or older. Population differences also appeared within the same survey: prevalence was 6.8% among non-Hispanic Black adults, compared with 12.9% among non-Hispanic White adults, 18.4% among non-Hispanic Asian adults, and 14.7% among Hispanic adults; differences among the latter three groups were not statistically significant. These are survey population categories, not explanations of the mechanisms underlying the differences. (cdc.gov)\n\nLower densitometric prevalence in men does not imply a proportionately negligible fracture burden. The China Osteoporosis Prevalence Study, conducted in 2017–2018 and published by Linhong Wang and colleagues in 2021, enrolled 20,416 adults. Among those aged 40 years or older, osteoporosis prevalence was 5.0% in men and 20.6% in women, whereas radiographically identified vertebral fractures affected 10.5% and 9.7%, respectively. Among participants with densitometric osteoporosis or fracture, only 0.3% of men and 1.4% of women were receiving antiosteoporosis treatment. The 2024 international guideline on osteoporosis in men identified the historical emphasis on women in research and clinical practice, together with uncertainty about male diagnosis, as contributors to underdiagnosis and consequent undertreatment. (jamanetwork.com)\n\nHip-fracture incidence varies substantially even after adjustment for population age and sex. A 2023 study by Ching-Lung Cheung, Chor-Wing Sing, and collaborators analyzed 4.1 million hip fractures in healthcare databases from 19 countries and regions during 2005–2018. Standardized rates among adults aged 50 years or older ranged from 95.1 per 100,000 population in the Brazilian database to 315.9 in Denmark. Proposed contributors to geographical and temporal differences include smoking and alcohol patterns, body mass, nutrition, fall prevention, and access to osteoporosis care. However, the observational databases could not establish their individual contributions; hospital-based ascertainment also omitted fractures without admission. (academic.oup.com)\n\nPopulation aging can increase absolute fracture numbers even where standardized incidence declines. The same multinational study projected a 1.9-fold increase in annual hip fractures between 2018 and 2050 across its comparable study populations, with a larger increase in men—2.4-fold—than in women—1.7-fold. Japan and US Medicare populations were excluded from this pooled projection because their populations were not directly comparable. These are conditional projections based on demographic forecasts and incidence trends, not a complete worldwide count or a forecast of densitometric osteoporosis prevalence. (academic.oup.com)"
    },
    {
      "heading": "Clinical features and fractures",
      "text": "The principal clinical manifestations are fractures and their consequences, rather than symptoms caused by low bone density itself. Fragile bones may break after a fall from standing height, or under ordinary loads such as bending, lifting, or coughing. The spine, hip, and wrist are characteristic sites, although other bones may be affected. Pain therefore varies with the location and severity of injury; the absence of pain does not exclude a vertebral fracture. (niams.nih.gov)\n\nVertebral compression fractures involve collapse and loss of height of a vertebral body. A symptomatic fracture may produce severe back pain, whereas many fractures remain clinically unrecognized. Repeated vertebral collapse produces cumulative height loss and kyphosis, the forward curvature responsible for a stooped posture. Persistent pain and altered posture can restrict walking, bending, and independent daily activities. Multiple thoracic fractures may also restrict lung expansion. Importantly, an apparently silent fracture is not clinically inconsequential: the Bone Health and Osteoporosis Foundation’s 2022 clinician’s guide reports that vertebral fractures are associated with approximately fivefold greater risk of further vertebral fractures and two- to threefold greater risk of fractures at other sites. (niams.nih.gov)\n\nHip fractures have particularly serious functional consequences. Hospitalization, surgery, and subsequent rehabilitation interrupt mobility, and some patients require continuing assistance or cannot return to their previous residence. Acute care also addresses complications such as delirium and pressure ulcers; recovery of walking and independence is a central objective of coordinated care. (nice.org.uk) Increased mortality extends beyond the immediate admission. A Danish nationwide cohort study published in 2010 followed more than 41,000 people with hip fractures sustained during 1999–2002: mortality within 12 months was 37.1% in men and 26.4% in women, compared with 9.9% and 9.3%, respectively, in the corresponding general population. These figures describe that cohort, not a universal prognosis. A 2017 analysis of eight European and US cohorts, comprising 122,808 participants, found an adjusted mortality hazard ratio of 2.78 during the first year after hip fracture and persistent excess mortality thereafter. Such observational associations include the influence of underlying frailty and illness as well as consequences of the injury. (pubmed.ncbi.nlm.nih.gov)\n\nWrist fractures, usually involving the distal radius, and proximal humerus fractures near the shoulder are important warning events. Wrist fractures often occur earlier than hip fractures, commonly between ages 50 and 60, and may impair activities necessary for independent living. (cdn.reachmd.com) Their significance extends beyond the injured arm. In a 1993 follow-up study, women aged 60–79 with a distal radius fracture had a subsequent hip-fracture relative risk of 1.9 compared with the background population. In a 2009 study by Jeremiah Clinton and colleagues involving 8,049 older white women, a proximal humerus fracture was associated with a hip-fracture hazard ratio of 5.68 during the following year after adjustment for other risk factors. The latter result was specific to this population and time interval; the association was not statistically significant beyond the first year. (pubmed.ncbi.nlm.nih.gov)\n\nFracture-related disability affects quality of life through pain, restricted movement, altered posture, and dependence on others. Psychological effects include depressive symptoms and loss of self-esteem, alongside physical limitations. These consequences can persist beyond fracture healing, particularly when vertebral deformity or impaired mobility remains. Upper-limb fractures also impose substantial burdens despite generally being less disabling than hip or vertebral fractures, because painful or restricted arm function interferes with independent daily activities. (cdn.reachmd.com)"
    },
    {
      "heading": "Diagnosis by bone mineral density",
      "text": "Dual-energy X-ray absorptiometry (DXA) is the standard method for measuring bone mineral density (BMD) for diagnostic classification. It uses X-rays at two energy levels to distinguish bone mineral from surrounding soft tissue, reporting mineral mass divided by projected bone area in \\(\\mathrm{g/cm^2}\\). Routine central DXA measures the lumbar spine, usually vertebrae L1–L4, and the proximal femur, with separate femoral-neck and total-hip results. The non-dominant forearm’s one-third, or 33%, radius is an alternative diagnostic site when the spine or hip cannot be measured or interpreted, when body weight exceeds the scanner’s table limit, or in hyperparathyroidism. Other forearm regions and the hip’s Ward’s area are not interchangeable diagnostic sites. (doi.org)\n\nThe T-score expresses the difference between measured BMD and the mean BMD of a young-adult reference population in units of standard deviation: \\(T=(BMD_{\\mathrm{patient}}-\\mu_{\\mathrm{young}})/\\sigma_{\\mathrm{young}}\\). Under the World Health Organization classification, normal density corresponds to \\(T\\geq-1.0\\), low bone mass—also called osteopenia—to \\(-2.5<T<-1.0\\), and osteoporosis to \\(T\\leq-2.5\\). Thus, a T-score of −2.7 means 2.7 standard deviations below the reference mean, not a 27% density deficit. These categories apply to postmenopausal women and men aged 50 years or older. Although the international reference standard is femoral-neck BMD, clinical densitometric diagnosis also accepts qualifying lumbar-spine or total-hip measurements, and the one-third radius in specified circumstances. (cdn.reachmd.com)\n\nReference-population choice affects the numerical score. The International Society for Clinical Densitometry’s 2023 positions specify a uniform White female young-adult reference for T-scores in women and men of all ethnic groups. Femoral-neck and total-hip calculations use the Third National Health and Nutrition Examination Survey (NHANES III), with women aged 20–29 years defining the femoral-neck reference; lumbar-spine calculations generally use manufacturers’ databases. By contrast, the Z-score compares BMD with an age- and sex-matched population, incorporating population-specific reference data where adequate. Z-scores are preferred before menopause and in men younger than 50: \\(Z\\leq-2.0\\) denotes density below the expected range for age, rather than automatically establishing osteoporosis. (iscd.org)\n\nDensitometric classification is not the only route to diagnosis. In postmenopausal women and men aged 50 years or older, a low-trauma hip or vertebral fracture can establish osteoporosis regardless of BMD, after evaluation excludes another explanation for skeletal fragility. A person with a hip fracture and a T-score of −1.8 may therefore have clinical osteoporosis despite falling within the densitometric low-bone-mass category. The Bone Health and Osteoporosis Foundation’s 2022 Clinician’s Guide also states that an established diagnosis persists when subsequent measurements rise above −2.5. Fracture history and density classification consequently describe related but distinct aspects of skeletal disease. (pmc.ncbi.nlm.nih.gov)\n\nDXA measures two-dimensional areal density, not true volumetric density: smaller bones can yield lower values and larger bones higher values despite similar mineral density per unit volume. Spinal osteoarthritis, osteophytes, vertebral compression, and implanted hardware can distort results, often artificially raising lumbar BMD and concealing bone loss. Structurally abnormal or artifact-affected vertebrae are excluded; at least two evaluable vertebrae are needed for spine-based classification. Positioning, region selection, and instrument calibration also affect measurements. Moreover, low BMD is not specific to osteoporosis: osteomalacia can also produce low values, requiring clinical and laboratory differentiation. (doi.org)\n\nQuantitative ultrasound, usually performed at the heel, can provide information relevant to fracture probability, but its device-specific measurements and T-scores are not equivalent to central-DXA results. WHO densitometric thresholds therefore cannot simply be applied to ultrasound scores. The UK National Osteoporosis Guideline Group’s December 2024 update explicitly states that quantitative ultrasound is not recommended for diagnosing osteoporosis; it does not substitute for validated DXA measurements in this classification. (iscd.org)"
    },
    {
      "heading": "Fracture-risk assessment and screening",
      "text": "FRAX estimates the 10-year probability of hip fracture and of a major osteoporotic fracture, defined as a hip, clinical vertebral, distal forearm, or proximal humerus fracture. It combines age, sex, height and weight with previous fracture, parental hip fracture, smoking, glucocorticoid exposure, rheumatoid arthritis, secondary osteoporosis, and alcohol consumption. Femoral-neck bone mineral density (BMD) is optional: an initial calculation without BMD can identify people whose assessment may benefit from dual-energy X-ray absorptiometry (DXA), after which risk is recalculated. Country-specific models reflect differences in fracture incidence and mortality; because death competes with fracture, the output is a probability rather than simply an accumulated fracture rate. FRAX is designed for ages 40–90. Its standard inputs do not fully represent fracture recency, multiple previous fractures, falls, or glucocorticoid dose, so these require separate clinical consideration. (fraxplus.org)\n\nVertebral fracture assessment (VFA) detects fractures that may not have produced recognized symptoms. Lateral thoracic and lumbar images can be acquired during DXA, with substantially less radiation than conventional spinal radiographs. Identifying an otherwise unrecognized moderate or severe vertebral fracture changes risk classification because such fractures predict further spinal and non-spinal fractures independently of BMD. The UK National Osteoporosis Guideline Group’s 2024 recommendations identify several indications for VFA in postmenopausal women and men aged at least 50: historical height loss of at least 4 cm, kyphosis, recent or ongoing long-term oral glucocorticoid exposure, a spine or hip T-score of \\(\\leq -2.5\\), or acute back pain accompanied by osteoporosis risk factors. Existing chest or abdominal radiographs can also reveal previously unreported vertebral fractures. (nogg.org.uk)\n\nOpportunistic assessment uses computed tomography (CT) obtained for another indication, avoiding an additional imaging exposure. Trabecular attenuation within a vertebral body provides a bone-density surrogate, while sagittal reconstructions show vertebral compression fractures. In a 2013 study by Perry Pickhardt and colleagues involving 1,867 adults, an L1 attenuation threshold of 160 Hounsfield units or less was 90% sensitive for DXA-defined osteoporosis; a threshold of 110 units was more than 90% specific. Among 119 patients with moderate-to-severe vertebral fractures, 52.1% did not have osteoporotic DXA T-scores. These study thresholds illustrate case-finding performance rather than a universal diagnostic definition. NOGG also distinguishes calibrated quantitative CT measurements of femoral-neck areal BMD, which can support opportunistic diagnosis and FRAX assessment, from simple vertebral attenuation measurements. (pubmed.ncbi.nlm.nih.gov)\n\nScreening policies distinguish population-wide testing from targeted risk assessment. On January 14, 2025, the US Preventive Services Task Force reaffirmed screening women aged 65 or older and postmenopausal women younger than 65 whose clinical risk assessment indicates increased fracture risk; both received grade B recommendations. Screening consists of DXA, with or without fracture-risk assessment. For men, evidence remained insufficient to determine the balance of screening benefits and harms—an evidence gap rather than a recommendation against testing. These recommendations concern adults without known osteoporosis or previous fragility fractures and exclude secondary osteoporosis and medication-associated bone loss. By contrast, NOGG’s 2024 pathway emphasizes FRAX-based case-finding in postmenopausal women and men aged at least 50 who have clinical risk factors. (uspreventiveservicestaskforce.org)\n\nNICE guideline NG259, published on July 29, 2026, replaced CG146, originally published in August 2012. It retains consideration of fracture-risk assessment for all women aged at least 65 and men aged at least 75, but more explicitly defines assessment after fractures and glucocorticoid exposure. In people aged at least 50 and women who have experienced menopause, previous fragility fracture or current or frequent systemic glucocorticoid use triggers assessment. NG259 permits direct DXA referral, without first completing a prediction tool, for adults aged at least 30 with a previous hip or vertebral fragility fracture, a single major osteoporotic fragility fracture within two years, or at least two fragility fractures. Otherwise, it specifies consideration of DXA at a 10-year major-fracture risk of at least 10%. This is a scanning threshold, not an automatic treatment threshold; CG146 had instead linked scanning to proximity to locally defined intervention thresholds. (scribd.com)"
    },
    {
      "heading": "Prevention and non-drug management",
      "text": "Adequate nutrition supplies the materials needed for bone maintenance: calcium is a major component of bone mineral, while vitamin D supports intestinal calcium absorption. The US Bone Health and Osteoporosis Foundation specifies total daily calcium intakes of 1,000 mg for men through age 70 and women through age 50, and 1,200 mg for older adults in these groups; its vitamin D intake recommendation for adults aged 50 and over is 800–1,000 international units (IU) daily. These calcium totals include food and supplements, rather than representing supplement doses. Dietary sources include milk, yogurt, calcium-fortified plant beverages, calcium-set tofu, and fish with edible bones. Supplements fill dietary shortfalls; intake beyond requirements has no established additional skeletal benefit. (bonehealthandosteoporosis.org)\n\nThe effects of supplementation depend on the population and cannot be inferred simply from these nutrients’ physiological importance. In Marie-Claude Chapuy and colleagues’ 1992 randomized controlled trial in elderly women, combined calcium and vitamin D produced 43% fewer hip fractures and 32% fewer nonvertebral fractures among participants completing 18 months of follow-up. By contrast, the 2022 VITAL fracture study, led by Meryl LeBoff, enrolled 25,871 US adults not selected for vitamin D deficiency, low bone mass, or osteoporosis. Vitamin D at 2,000 IU daily did not reduce fractures over a median 5.3 years: the hazard ratio for total fractures was 0.98, with a 95% confidence interval of 0.89–1.08. A 2026 systematic review of 69 trials involving 153,902 participants likewise found little or no clinically meaningful fracture or fall prevention from routine calcium, vitamin D, or combined supplementation. (nejm.org)\n\nCorrection of nutritional inadequacy is therefore distinct from indiscriminate supplementation of adequately nourished adults. The UK National Osteoporosis Guideline Group (NOGG) targets calcium and vitamin D supplementation particularly to people with insufficient intake, including housebound adults, care-home residents, and people with intestinal malabsorption. Calcium and vitamin D supplements can increase kidney-stone risk, and large intermittent vitamin D doses have sometimes increased falls or fractures. Nutritional measures accompany, rather than replace, osteoporosis medication when fracture risk warrants pharmacological treatment; most pivotal drug trials included calcium and vitamin D alongside the active treatment. (nogg.org.uk)\n\nExercise addresses both skeletal loading and the muscular functions needed to avoid falls. Weight-bearing activities load bones through gravity and ground-reaction forces, whereas resistance exercise adds loading through muscle contraction. The 2022 Strong, steady and straight UK consensus statement distinguishes exercise for bone strength, balance training for steadiness, and spinal-extension exercises for posture. It describes progressive muscle-strengthening activity on two or three days weekly, using major muscle groups to load sites such as the hip, spine, and forearm. Exercise generally produces modest, site-specific improvements in bone mineral density; evidence that these changes directly prevent fractures is less certain. Exercise intensity and movements are adapted in people with vertebral fractures or substantial fall risk, particularly where repeated or loaded spinal flexion is involved. (pmc.ncbi.nlm.nih.gov)\n\nEvidence is stronger for reducing falls than for preventing fractures through exercise alone. Cathie Sherrington and colleagues’ 2019 Cochrane review included 108 trials and 23,407 community-dwelling older adults. Exercise reduced the rate of falls by 23%, with high-certainty evidence; effective programmes primarily involved balance and functional training, often combined with resistance exercise. Walking or resistance training alone had less certain effects on falls. Individualized fall-prevention programmes also assess medication-related risks, vision, mobility, and environmental hazards. The 2024 US Preventive Services Task Force evidence review found that multifactorial programmes reduced fall rates, but did not demonstrate a statistically significant reduction in fall-related fractures. (cochrane.org)\n\nSmoking cessation and reduction of excessive alcohol consumption are additional components of non-drug management. Their fracture-specific evidence is largely observational rather than derived from intervention trials. NOGG cites lower vertebral and hip fracture risk in women who stopped smoking, although the hip-fracture association became apparent only after five years. In men with previous alcohol dependence, bone mineral density improved after three to four years of abstinence. These findings concern gradual changes in skeletal health, not immediate reversal of established osteoporosis. (nogg.org.uk)"
    },
    {
      "heading": "Antiresorptive pharmacological treatments",
      "text": "Bisphosphonates inhibit osteoclast-mediated bone resorption. Nitrogen-containing agents, including alendronate and zoledronic acid, inhibit farnesyl pyrophosphate synthase in the mevalonate pathway, disrupting the protein prenylation required for osteoclast function and survival. Common regimens are oral alendronate 70 mg weekly and intravenous zoledronic acid 5 mg annually. Alendronate can cause upper gastrointestinal irritation; zoledronic acid can produce a transient influenza-like reaction after infusion, particularly the first dose, and has restrictions in severe renal impairment. In Dennis M. Black and colleagues’ 2007 HORIZON Pivotal Fracture Trial, annual zoledronic acid reduced three-year radiographic vertebral-fracture incidence from 10.9% to 3.3% and hip-fracture incidence from 2.5% to 1.4%, corresponding to relative reductions of 70% and 41%. (pubmed.ncbi.nlm.nih.gov)\n\nDenosumab is a human monoclonal antibody against RANKL, the signaling molecule required for osteoclast formation, activity, and survival. It is administered subcutaneously at 60 mg every six months. Steven R. Cummings and colleagues’ 2009 FREEDOM randomized controlled trial enrolled 7,868 postmenopausal women aged 60–90 years. Over three years, new radiographic vertebral fractures occurred in 2.3% of denosumab recipients and 7.2% of placebo recipients; hip fractures occurred in 0.7% and 1.2%, respectively. These represented relative reductions of 68% and 40%; nonvertebral fractures were reduced by 20%. (accessdata.fda.gov)\n\nDenosumab’s suppression of resorption reverses after discontinuation. Bone turnover can rise above pretreatment levels, bone density falls rapidly, and multiple vertebral fractures may occur, particularly in patients with previous vertebral fractures. Consequently, its discontinuation differs from a bisphosphonate treatment interruption: another antiresorptive is generally incorporated into the discontinuation strategy. Denosumab can also cause hypocalcemia. On January 19, 2024, the US Food and Drug Administration announced a boxed warning concerning severe hypocalcemia in patients with advanced chronic kidney disease, especially those receiving dialysis or with associated mineral and bone disorder; reported outcomes included hospitalization, life-threatening events, and death. (accessdata.fda.gov)\n\nSelective estrogen receptor modulators have tissue-dependent estrogen-like or estrogen-antagonist effects. Raloxifene, given orally at 60 mg daily, inhibits bone resorption and is used in postmenopausal women. Bruce Ettinger and colleagues’ 1999 MORE trial found that three-year vertebral-fracture incidence was 6.6% with this dose versus 10.1% with placebo, but nonvertebral-fracture risk was not significantly reduced. Hip-fracture protection has not been established. Its adverse effects include hot flushes and increased venous thromboembolism risk; its reduction of estrogen-receptor-positive breast-cancer risk can also influence treatment selection. (nogg.org.uk)\n\nMenopausal hormone therapy also suppresses bone resorption. Its place in osteoporosis treatment depends on age, menopausal symptoms, formulation, and baseline risks. The 2024 UK NOGG guideline identifies it as a possible first-line option for selected postmenopausal women aged 60 years or younger with high fracture risk and low malignant and thromboembolic risk. In the Women’s Health Initiative trial reported in 2002, oral conjugated equine estrogens plus medroxyprogesterone acetate reduced hip fractures but increased coronary events, stroke, pulmonary embolism, and invasive breast cancer. These findings concern that particular combined regimen rather than every hormone formulation or route. (nogg.org.uk)\n\nRare adverse effects of bisphosphonates and denosumab include osteonecrosis of the jaw and atypical femoral fractures. Jaw osteonecrosis involves persistent exposed or probeable jawbone and is associated with dental disease and invasive dental procedures; it is substantially more frequent with oncology-dose treatment than osteoporosis-dose treatment. NOGG cites an estimated incidence of 10–100 cases per 100,000 person-years for bisphosphonate-associated jaw osteonecrosis in osteoporosis trials. Atypical femoral fractures usually involve the subtrochanteric region or femoral shaft, may be bilateral, and can be preceded by thigh or groin pain. Reported absolute risks with bisphosphonates are approximately 3.2–50 per 100,000 person-years, increasing with prolonged exposure and declining after discontinuation. (nogg.org.uk)"
    },
    {
      "heading": "Bone-forming treatments and treatment sequencing",
      "text": "Bone-forming, or anabolic, treatments are used particularly in patients at very high fracture risk, including those with severe or multiple vertebral fractures. Teriparatide is the biologically active 1–34 fragment of parathyroid hormone, whereas abaloparatide is an analogue of parathyroid hormone-related peptide. Both activate the PTH1 receptor; intermittent daily exposure stimulates osteoblast-mediated formation, although bone resorption also increases. Their subcutaneous doses are 20 micrograms daily and 80 micrograms daily, respectively. Unlike continuous excess parathyroid hormone, intermittent teriparatide administration produces a net anabolic skeletal effect. (nogg.org.uk)\n\nRomosozumab is a monoclonal antibody against sclerostin, an inhibitor of bone formation. It has a dual action: increasing formation while reducing resorption. The dose is 210 mg subcutaneously monthly, administered as two 105-mg injections, for 12 doses; its anabolic effect wanes during this period. In the United States, it is indicated for postmenopausal women at high fracture risk, including those whose other treatments have failed or are not tolerated. Its boxed cardiovascular warning states that treatment should not begin in patients who experienced myocardial infarction or stroke within the preceding year. (dailymed.nlm.nih.gov)\n\nTreatment duration differs between agents and jurisdictions. UK NOGG guidance specifies courses of 24 months for teriparatide, 18 months for abaloparatide, and 12 months for romosozumab. US teriparatide labeling permits consideration of treatment beyond two years only when a patient remains at, or returns to, high fracture risk; US abaloparatide labeling does not recommend lifetime use exceeding two years. Completion of an anabolic course is normally followed promptly by an antiresorptive such as alendronate, zoledronic acid, or denosumab. This subsequent phase preserves the increased bone mineral density, which otherwise declines after withdrawal; the transition is therefore planned when anabolic therapy begins rather than treated as an optional later addition. (nogg.org.uk)\n\nThe order of treatment affects outcomes. In the 2017 ARCH randomized controlled trial, Kenneth G. Saag and colleagues enrolled 4,093 postmenopausal women with osteoporosis and a fragility fracture. Twelve months of romosozumab followed by alendronate produced fewer new vertebral fractures at 24 months than alendronate throughout: 6.2% versus 11.9%, a 48% relative reduction. Hip fracture incidence at the primary analysis was 2.0% versus 3.2%. (nejm.org) Conversely, the 2015 DATA-Switch trial, led by Benjamin Z. Leder, found that changing from teriparatide to denosumab continued to increase bone density, whereas changing from denosumab to teriparatide caused transient loss at the spine and hip and progressive loss at the radius. These findings demonstrate that reversing a successful sequence does not necessarily reproduce its benefits. (pmc.ncbi.nlm.nih.gov)\n\nA “drug holiday” is distinct from the transition after anabolic treatment. The Endocrine Society’s 2019 guideline recommends reassessing fracture risk after three to five years of bisphosphonate therapy; patients remaining at high risk generally continue treatment, whereas those at low-to-moderate risk may have a temporary interruption. Residual protection is best supported for alendronate and zoledronic acid. During a holiday, reassessment at two-to-four-year intervals may identify substantial bone-density loss, an intervening fracture, or other reasons to restart treatment earlier. Denosumab does not have the same persistent skeletal effect: a holiday or unprotected interruption is not recommended. (endocrine.org)\n\nMonitoring evaluates both skeletal response and treatment adherence. Endocrine Society guidance specifies repeat dual-energy X-ray absorptiometry at the spine and hip every one to three years in treated high-risk postmenopausal women, with the interval adjusted to clinical circumstances. Bone-turnover biomarkers provide complementary information: serum procollagen type I N-terminal propeptide (P1NP) reflects formation and can help assess anabolic treatment, while serum C-terminal telopeptide of type I collagen (CTX) reflects resorption and can help assess antiresorptive treatment. An unexpectedly weak marker response can identify poor response or nonadherence for further evaluation. (endocrine.org)"
    },
    {
      "heading": "Special populations",
      "text": "In men, the 2024 guideline developed by Nicholas Fuggle and colleagues for the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) recommends a female reference database for densitometric diagnosis. At the femoral neck, this means using the young-adult female NHANES reference range rather than a male-specific range: hip-fracture risk is similar in men and women at a given absolute bone mineral density (BMD). The guideline supports FRAX assessment with age-dependent intervention thresholds and consideration of treatment in all men with a previous fragility fracture. It identifies alendronate or risedronate as first-line options at high risk, and bone-forming therapy followed by an antiresorptive at very high risk. Assessment of serum total testosterone is included in the pretreatment evaluation, although this recommendation is weaker than those concerning fracture-risk assessment and treatment. (esceo.org)\n\nGlucocorticoid exposure changes the relationship between BMD and fracture risk, so treatment eligibility does not depend solely on reaching a T-score of \\(-2.5\\). The 2022 American College of Rheumatology guideline, published in 2023, addresses adults receiving at least 2.5 mg/day of prednisone-equivalent glucocorticoid for more than three months. It recommends early assessment incorporating fracture history, BMD and vertebral imaging, with FRAX for those aged 40 or older. In this age group, moderate-risk criteria include a glucocorticoid-adjusted ten-year major osteoporotic fracture probability of \\(10\\%\\) to less than \\(20\\%\\), or a T-score between \\(-1.0\\) and \\(-2.4\\); pharmacological treatment is recommended for moderate, high and very high risk. Above 7.5 mg/day, the guideline adjusts FRAX major-fracture probability by a factor of 1.15 and hip-fracture probability by 1.20. FRAX is not validated for adults younger than 40, whose assessment instead emphasizes fractures, exposure and age-adjusted BMD. (acrjournals.onlinelibrary.wiley.com)\n\nEthnicity and migration require attention to the population in which a prediction model was calibrated. The UK National Osteoporosis Guideline Group (NOGG) 2024 guideline notes that UK FRAX probabilities predominantly reflect a white population. For people who migrated to the United Kingdom, it supports using the country-of-birth model where available, while acknowledging uncertainty about how quickly risk changes in subsequent generations. Parkinson’s disease also increases fracture risk independently of BMD. NOGG describes entering “yes” in the rheumatoid arthritis field as a surrogate adjustment for Parkinson’s disease, not as a diagnosis of arthritis; this only partly captures the additional risk. (nogg.org.uk)\n\nNOGG also lists Down syndrome and lower-limb amputation as conditions that warrant consideration in fracture-risk assessment. Amputation can produce substantial side-to-side differences that a single skeletal measurement may obscure: a 2003 study of 99 lower-limb amputees found femoral-neck BMD approximately 10.4% lower on the amputated side than on the intact side. A separate study of 14 amputees found lower proximal-femoral BMD on the amputated side, with the largest differences in above-knee amputees. These observations distinguish regional bone deficits after limb loss from an assumption of uniform skeletal involvement. (nogg.org.uk)\n\nIn children and adolescents, low BMD alone does not establish osteoporosis. The International Society for Clinical Densitometry’s 2019 positions define one or more vertebral compression fractures as diagnostic in the absence of local disease or high-energy trauma. Otherwise, diagnosis requires both a BMD Z-score of \\(\\leq -2.0\\) and a significant fracture history: at least two long-bone fractures by age ten, or three by age nineteen. Pediatric reports use Z-scores rather than T-scores. Spine and total-body-less-head measurements are preferred in most children, with adjustment for short stature or growth delay to avoid interpreting small bone size as deficient mineralization. A Z-score above \\(-2.0\\) does not exclude skeletal fragility. (iscd.org)\n\nChronic illnesses can require additional distinctions between osteoporosis and other skeletal disorders. In chronic kidney disease, DXA predicts fracture risk but cannot distinguish the different forms of renal osteodystrophy. KDIGO’s 2017 guideline supports BMD testing in stages G3a–G5D when results would affect treatment decisions. Where low BMD or fragility fractures coexist with biochemical abnormalities of mineral and bone metabolism, treatment assessment incorporates those abnormalities and the progression of kidney disease. A bone biopsy may clarify the underlying disorder when that information would change treatment, but is not a universal prerequisite for antiresorptive therapy. (kdigo.org)"
    },
    {
      "heading": "History of discovery and diagnostic criteria",
      "text": "In 1822, the British surgeon and anatomist Astley Paston Cooper described an association between abnormal bone and fractures. Jean Lobstein subsequently used the term osteoporosis in his nineteenth-century pathological descriptions; a major historical review dates this usage to 1835. Lobstein’s description included blue-grey sclerae and probably concerned osteogenesis imperfecta rather than the age-related disorder now called osteoporosis. The early terminology therefore identified porous or fragile bone without yet distinguishing the different diseases that could produce it. (onlinelibrary.wiley.com)\n\nPostmenopausal osteoporosis became a more clearly defined clinical entity through the work of Fuller Albright, Patricia H. Smith, and Anna M. Richardson at Massachusetts General Hospital and Harvard Medical School. Their paper, “Postmenopausal Osteoporosis: Its Clinical Features,” appeared in JAMA on May 31, 1941. It distinguished osteoporosis, in which the amount of bone matrix was reduced, from osteomalacia, in which deposited matrix was inadequately mineralized. Albright associated vertebral fractures with loss of ovarian function; observations that estrogen treatment improved calcium balance and arrested height loss helped establish the connection between menopause, ovarian hormones, and skeletal deterioration. His explanation emphasized inadequate bone formation, rather than the increased bone resorption subsequently recognized as an important consequence of estrogen deficiency. (jamanetwork.com)\n\nQuantitative bone measurement changed identification of the disease from recognition of fractures and skeletal deformity to detection of low bone mass before fracture. In 1963, John R. Cameron and James Sorenson described single-photon absorptiometry: mineral content was estimated from attenuation of a monochromatic photon beam from a radioactive source, commonly iodine-125, as it passed through bone. This method was particularly suited to peripheral sites such as the radius. Dual-photon absorptiometry subsequently enabled measurements at the spine and hip. In the late 1980s, dual-energy X-ray absorptiometry (DXA) replaced radionuclide sources with an X-ray tube, improving scanning speed and precision and making repeated measurements more practical. (pubmed.ncbi.nlm.nih.gov)\n\nThe World Health Organization study-group report Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis, published in 1994 as Technical Report Series 843, established an operational classification based on bone mineral density. John A. Kanis and colleagues also presented the diagnostic framework that year. The T-score expressed density relative to the young-adult reference mean in units of standard deviation: normal density was \\(T \\geq -1\\), osteopenia was \\(-2.5 < T < -1\\), and osteoporosis was \\(T \\leq -2.5\\). “Severe” or “established” osteoporosis combined the osteoporosis-range density with one or more fragility fractures. Developed for postmenopausal women, this framework standardized research populations and enabled a densitometric diagnosis before a fracture occurred. (pubmed.ncbi.nlm.nih.gov)\n\nDrug development made this earlier identification clinically consequential. Alendronate, a bisphosphonate that inhibits bone resorption, received United States approval in 1995; its introduction encouraged wider use of densitometry. The 1996 Fracture Intervention Trial report, led by Dennis M. Black and colleagues, provided evidence from a randomized controlled trial involving 2,027 women with low bone mass and existing vertebral fractures. Over 36 months, new radiographically identified vertebral fractures occurred in 8.0% of alendronate recipients and 15.0% of placebo recipients. Thus, treatment efficacy was demonstrated through fracture outcomes, not merely increases in measured density. (pubmed.ncbi.nlm.nih.gov)\n\nBone-forming treatment introduced a different therapeutic approach. A 2001 trial led by Robert M. Neer enrolled 1,637 postmenopausal women with previous vertebral fractures: new vertebral fractures occurred in 14% of placebo recipients and 5% of women receiving daily 20-microgram parathyroid hormone (1–34), subsequently marketed as teriparatide and approved in the United States in 2002. Later milestones included denosumab approval in 2010, introducing targeted RANKL inhibition through a monoclonal antibody, and romosozumab approval in 2019. Romosozumab’s inhibition of sclerostin increased bone formation while also decreasing resorption, extending treatment beyond suppression of bone loss alone. (pubmed.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Public health, health economics, and care models",
      "text": "The economic burden of osteoporosis falls predominantly on fracture care rather than on preventive medication. The SCOPE 2021 study estimated total direct expenditure of €56.9 billion in 2019 across the 27 European Union countries, the United Kingdom, and Switzerland: €36.3 billion for newly occurring fractures, €19.0 billion for continuing consequences of earlier fractures, and €1.6 billion for assessment and pharmacological treatment. This represented approximately 3.5% of healthcare expenditure in those countries. Hip fractures accounted for about 57% of costs, reflecting their disproportionate demand for hospital treatment and continuing care. These estimates exclude the monetary value of lost quality of life and therefore are not a complete measure of societal burden. (pmc.ncbi.nlm.nih.gov)\n\nCosts extend beyond surgery and the initial hospital admission to rehabilitation, community services, and residential or nursing-home care. Economic evaluations consequently distinguish immediate hospital expenditure from lifetime health and social-care costs. A 2017 UK modelling study compared usual post-hip-fracture care with nurse-led fracture liaison and orthogeriatric services, using a base-case population aged 83 years. Orthogeriatric care—which integrates geriatric and orthopaedic management—was the most cost-effective model at a threshold of £30,000 per quality-adjusted life year gained. The analysis nevertheless identified substantial uncertainty about the relative effects of the service models on survival and subsequent fractures; cost-effectiveness estimates are therefore dependent on local service organization and modelling assumptions. (pmc.ncbi.nlm.nih.gov)\n\nA fracture liaison service (FLS) organizes secondary prevention after a fragility fracture rather than leaving osteoporosis assessment to an incidental referral. A coordinator, commonly a specialist nurse, links fracture clinics, osteoporosis assessment, prescribing, falls services, and primary care. A Glasgow service described by Mayrine Fraser and Alastair R. McLellan in 2004 offered assessment to men and women older than 50 with new fractures. The UK National Osteoporosis Guideline Group (NOGG) recommends multidisciplinary, coordinator-based services providing fracture-risk and falls assessment, investigation, treatment, and monitoring. Its care-model guidance supports follow-up within 16 and 52 weeks after fracture to review medication use, adverse effects, and adherence. This longitudinal responsibility distinguishes an FLS from a one-time screening appointment. (pubmed.ncbi.nlm.nih.gov)\n\nGuidelines provide different but complementary frameworks for organizing care. NOGG’s September 2024 recommendations apply to postmenopausal women and men aged at least 50, linking fracture-risk categories to investigation, treatment, and specialist referral. In England, the National Institute for Health and Care Excellence (NICE) addresses both clinical assessment and the economic appraisal of medicines: its CG146 guideline covers fragility-fracture risk assessment, while technology appraisal TA464 evaluates bisphosphonate treatment. NICE’s January 2026 consultation draft proposed a two-stage consolidation, separating assessment and treatment criteria from subsequent recommendations on treatment and monitoring. This draft should be distinguished from published guidance rather than treated as an already implemented standard. (nogg.org.uk)\n\nIn the United States, the AACE/ACE 2020 guideline differentiates high from very high fracture risk. Its algorithm includes treatment thresholds of a 10-year major osteoporotic fracture probability of at least 20% or hip-fracture probability of at least 3%, alongside fracture history and bone-density criteria; it explicitly notes that other countries may use different thresholds. The Endocrine Society’s 2019 guideline, updated in 2020, prioritizes high-risk postmenopausal women, particularly those with previous fractures, and incorporates reassessment and treatment sequencing. These documents translate clinical evidence into care pathways, but they do not establish identical eligibility or reimbursement rules across health systems. (pro.aace.com)\n\nImplementation remains limited by missed diagnoses, incomplete post-fracture follow-up, and restricted access to investigations and medicines. SCOPE estimated that 71% of women eligible for treatment in the surveyed European countries were untreated in 2019. The International Osteoporosis Foundation’s 2025 position paper identified a particularly important access mechanism: reimbursement may require densitometric confirmation even where dual-energy X-ray absorptiometry is scarce. It also identified confusion between diagnostic thresholds and treatment thresholds as a barrier. Thus, a clinically recognized fragility fracture or high fracture risk may fail to produce funded treatment when administrative eligibility depends on a test that is unavailable. (osteoporosis.foundation)"
    },
    {
      "heading": "Unresolved questions and controversies",
      "text": "The optimal duration of bisphosphonate treatment remains uncertain because evidence beyond the initial treatment course comes chiefly from two extension trials. FLEX found fewer clinical vertebral fractures with ten years of alendronate than with discontinuation after five years; the HORIZON extension found fewer radiographically identified vertebral fractures with six years of zoledronic acid than with discontinuation after three. These findings did not establish a comparable benefit for every fracture outcome or population. The American Society for Bone and Mineral Research’s 2016 task force therefore proposed reassessment after five years of oral or three years of intravenous treatment, with longer treatment for high-risk patients and a possible two- to three-year “drug holiday” for lower-risk patients. The controversy concerns how to balance residual protection after discontinuation against the increasing risk of atypical femoral fracture during prolonged exposure. Evidence supporting these decisions is largely restricted to predominantly White postmenopausal women, leaving uncertainty about generalization to men and other populations. (asbmr.org)\n\nFRAX simplifies several risk factors into binary inputs, although their effects are graded. A single remote fracture and several recent fractures do not confer equivalent risk; glucocorticoid dose also matters. Standard FRAX does not directly incorporate fracture recency, while FRAXplus provides adjustments for additional information. Falls are another limitation of the original model. These omissions are particularly relevant when estimating near-term risk rather than ten-year probability. (fraxplus.org) Bone mineral density has a different limitation: equal measured density does not necessarily imply equal skeletal strength. In type 2 diabetes, density is commonly higher than in people without diabetes, yet fracture risk is higher at a given T-score or FRAX probability. Consequently, a reassuring density result may underestimate risk in this group. (diabetesjournals.org)\n\nMeasures beyond density offer supplementary information but have not replaced established assessment methods. The trabecular bone score analyzes texture in lumbar-spine DXA images as an indirect indicator of trabecular structure and can modify FRAX probabilities. The International Society for Clinical Densitometry’s 2023 positions identify its greatest potential usefulness near treatment thresholds, but explicitly state that it should not determine treatment by itself. Image artifacts and the manufacturer’s applicable body-mass-index range constrain interpretation. (iscd.org) Bone-turnover biomarkers are associated with fracture risk independently of density, but their incorporation into FRAX remains unresolved because standardized reference measures and sufficiently broad international experience are lacking. (fraxplus.org)\n\nConcerns about overdiagnosis and overtreatment distinguish a diagnostic label from a treatment likely to provide meaningful benefit. Low density alone does not settle the balance between fracture prevention, treatment burden, and competing illness in a person with limited life expectancy. A 2022 meta-analysis of ten randomized controlled trials, involving 23,384 postmenopausal women, estimated that 12.4 months of bisphosphonate treatment were needed to prevent one nonvertebral fracture per 100 treated women; preventing one hip fracture per 200 women required approximately 20.3 months. These are population estimates at specified absolute benefits, not individual survival cutoffs. (pmc.ncbi.nlm.nih.gov) Evidence in severe frailty also illustrates the distinction between surrogate and clinical outcomes: Susan Greenspan and colleagues’ 2015 trial in 181 nursing-home or assisted-living residents found that one zoledronic acid infusion improved density over two years, but was not designed to establish fracture reduction. This leaves uncertainty about benefit in a population that is simultaneously vulnerable to fractures and underrepresented in pivotal trials. (pmc.ncbi.nlm.nih.gov)\n\nArtificial intelligence can automate opportunistic analysis of existing CT examinations by segmenting vertebrae and measuring their attenuation. However, performance within a development setting may not transfer unchanged to other institutions. A multicenter study published online in October 2025 and in a May 2026 journal issue evaluated 504 participants: its area under the receiver-operating-characteristic curve for distinguishing normal density from osteoporosis fell from 0.96 internally to 0.82 externally. External sensitivity and specificity were 79% and 81%, respectively. These results illustrate why independent validation matters. Because the study measured diagnostic accuracy retrospectively, it did not establish whether automated alerts improve treatment uptake, reduce fractures, or produce an acceptable burden of false-positive follow-up examinations. (pubmed.ncbi.nlm.nih.gov)"
    }
  ],
  "links": [
    "cell",
    "hormone",
    "homeostasis",
    "nutrition",
    "disability",
    "mortality-rate",
    "public-health",
    "epidemiology",
    "world-health-organization",
    "standard-deviation",
    "collagen",
    "quality-of-life",
    "bone-marrow",
    "menopause",
    "apoptosis",
    "immune-system",
    "cytokine",
    "prednisone",
    "hyperthyroidism",
    "rheumatoid-arthritis",
    "chronic-kidney-disease",
    "genetics",
    "protein",
    "diabetes-mellitus",
    "dementia",
    "prevalence",
    "rehabilitation",
    "x-ray-computed-tomography",
    "randomized-controlled-trial",
    "monoclonal-antibody",
    "stroke",
    "biomarker",
    "down-syndrome",
    "biopsy",
    "x-ray",
    "evidence-based-medicine",
    "health-system",
    "type-two-diabetes",
    "life-expectancy",
    "artificial-intelligence"
  ],
  "sources": [
    {
      "title": "Osteoporosis Causes, Risk Factors, & Symptoms | NIAMS",
      "url": "https://www.niams.nih.gov/health-topics/osteoporosis?navPos=0"
    },
    {
      "title": "Fragility fractures",
      "url": "https://www.who.int/news-room/fact-sheets/detail/fragility-fractures"
    },
    {
      "title": "Official Adult Positions - ISCD",
      "url": "https://iscd.org/official-positions-2023/"
    },
    {
      "title": "Bone Mineral Density Tests: What the Numbers Mean | NIAMS",
      "url": "https://www.niams.nih.gov/health-topics/bone-mineral-density-tests-what-numbers-mean"
    },
    {
      "title": "The clinician’s guide to prevention and treatment of osteoporosis - PMC",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9546973/"
    },
    {
      "title": "The Basics of Bone in Health and Disease - Bone Health and Osteoporosis - NCBI Bookshelf",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK45504/"
    },
    {
      "title": "The Epidemiology and Pathogenesis of Osteoporosis - Endotext - NCBI Bookshelf",
      "url": "https://www.ncbi.nlm.nih.gov/sites/books/NBK279134/"
    },
    {
      "title": "OVERVIEW OF CALCIUM",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK56070/pdf/Bookshelf_NBK56070.pdf"
    },
    {
      "title": "Anatomy and Ultrastructure of Bone – Histogenesis, Growth and Remodeling - Endotext - NCBI Bookshelf",
      "url": "https://www.ncbi.nlm.nih.gov/sites/books/NBK279149/"
    },
    {
      "title": "4 The Physiology of Bone",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK565578/pdf/Bookshelf_NBK565578.pdf"
    },
    {
      "title": "Calcium and Phosphate Homeostasis - Endotext - NCBI Bookshelf",
      "url": "https://ncbi.nlm.nih.gov/books/NBK279023/?report=printable"
    },
    {
      "title": "Calcium - Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride - NCBI Bookshelf",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK109827/"
    },
    {
      "title": "Osteoporosis in Men",
      "url": "https://www.niams.nih.gov/health-topics/osteoporosis-men"
    },
    {
      "title": "The Epidemiology and Pathogenesis of Osteoporosis",
      "url": "https://www.endotext.org/wp-content/uploads/pdfs/the-epidemiology-and-pathogenesis-of-osteoporosis.pdf"
    },
    {
      "title": "Calcium and Phosphate Homeostasis",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK279023/"
    },
    {
      "title": "Osteoporosis: Clinical Evaluation",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK279049/"
    },
    {
      "title": "Osteoporosis Screening Evidence Review",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK611438/pdf/Bookshelf_NBK611438.pdf"
    },
    {
      "title": "Bone Health and Osteoporosis: A Report of the Surgeon General",
      "url": "https://www.ncbi.nlm.nih.gov/books/n/rptosteo/pdf/"
    },
    {
      "title": "Evidence for two distinct syndromes of involutional osteoporosis",
      "url": "https://pubmed.ncbi.nlm.nih.gov/6650542/"
    },
    {
      "title": "Glucocorticoid-Induced Osteoporosis",
      "url": "https://www.endocrine.org/patient-engagement/endocrine-library/glucocorticoid-induced-osteoporosis"
    },
    {
      "title": "An Overview of Glucocorticoid-Induced Osteoporosis",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK278968/"
    },
    {
      "title": "Table 1. Secondary Causes of Osteoporosis",
      "url": "https://www.ncbi.nlm.nih.gov/sites/books/NBK279073/table/osteoporosis-prevent.T.secondary_causes/"
    },
    {
      "title": "Juvenile Osteoporosis",
      "url": "https://www.niams.nih.gov/health-topics/juvenile-osteoporosis"
    },
    {
      "title": "Text Pediatric Positions",
      "url": "https://iscd.org/text-pediatric-positions/"
    },
    {
      "title": "Primary Osteoporosis in Young Adults: Genetic Basis and Identification of Novel Variants in Causal Genes",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6124172/"
    },
    {
      "title": "Osteoporosis Causes, Risk Factors, & Symptoms",
      "url": "https://www.niams.nih.gov/health-topics/osteoporosis/syndicate"
    },
    {
      "title": "Section 3: Fracture risk assessment and case finding",
      "url": "https://www.nogg.org.uk/full-guideline/section-3-fracture-risk-assessment-and-case-finding"
    },
    {
      "title": "Heritability of bone mineral density",
      "url": "https://pubmed.ncbi.nlm.nih.gov/10327493/"
    },
    {
      "title": "Section 7: Strategies for management of osteoporosis and fracture risk",
      "url": "https://www.nogg.org.uk/full-guideline/section-7-strategies-management-osteoporosis-and-fracture-risk"
    },
    {
      "title": "Frequently Asked Questions",
      "url": "https://www.nogg.org.uk/frequently-asked-questions"
    },
    {
      "title": "The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8522202/"
    },
    {
      "title": "Global, regional prevalence, and risk factors of osteoporosis according to the World Health Organization diagnostic criteria: a systematic review and meta-analysis",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35687123/"
    },
    {
      "title": "Products - Data Briefs - Number 405 - March 2021",
      "url": "https://www.cdc.gov/nchs/products/databriefs/db405.htm"
    },
    {
      "title": "QuickStats: Percentage of Adults Aged ≥50 Years with Osteoporosis, by Race and Hispanic Origin — United States, 2017–2018",
      "url": "https://www.cdc.gov/mmwr/volumes/70/wr/mm7019a5.htm"
    },
    {
      "title": "Evidence-Based Guideline for the management of osteoporosis in men",
      "url": "https://www.nature.com/articles/s41584-024-01094-9"
    },
    {
      "title": "The clinician’s guide to prevention and treatment of osteoporosis",
      "url": "https://cdn.reachmd.com/uploads/bhof_%28formerly_nof%29_oi_clinicians_guide_2022.pdf"
    },
    {
      "title": "Recommendations | Hip fracture: management | Guidance | NICE",
      "url": "https://www.nice.org.uk/guidance/cg124/chapter/recommendations"
    },
    {
      "title": "Hip fracture: full guideline",
      "url": "https://www.nice.org.uk/guidance/cg124/documents/hip-fracture-full-guideline2"
    },
    {
      "title": "Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival",
      "url": "https://pubmed.ncbi.nlm.nih.gov/20075035/"
    },
    {
      "title": "Excess mortality after hip fracture in elderly persons from Europe and the USA: the CHANCES project.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28093824/"
    },
    {
      "title": "Radial and humeral fractures as predictors of subsequent hip, radial or humeral fractures in women, and their seasonal variation",
      "url": "https://pubmed.ncbi.nlm.nih.gov/8481589/"
    },
    {
      "title": "Proximal humeral fracture as a risk factor for subsequent hip fractures",
      "url": "https://pubmed.ncbi.nlm.nih.gov/19255209/"
    },
    {
      "title": "Official Adult Positions - ISCD",
      "url": "https://iscd.org/official-positions-2023/?cn-reloaded=1"
    },
    {
      "title": "Updated practice guideline for dual-energy X-ray absorptiometry (DXA)",
      "url": "https://doi.org/10.1007/s00259-024-06912-6"
    },
    {
      "title": "NOGG 2024: Clinical guideline for the prevention and treatment of osteoporosis",
      "url": "https://www.nogg.org.uk/sites/nogg/download/NOGG-Guideline-2024.pdf?v3="
    },
    {
      "title": "NOGG 2024: Clinical guideline for the prevention and treatment of osteoporosis",
      "url": "https://www.nogg.org.uk/sites/nogg/download/NOGG-Guideline-2024.pdf"
    },
    {
      "title": "Summary of 2024 updates | NOGG",
      "url": "https://www.nogg.org.uk/full-guideline/summary-2024-updates"
    },
    {
      "title": "FAQ | FRAXplus®",
      "url": "https://www.fraxplus.org/faq"
    },
    {
      "title": "Opportunistic screening for osteoporosis using abdominal computed tomography scans obtained for other indications",
      "url": "https://pubmed.ncbi.nlm.nih.gov/23588747/"
    },
    {
      "title": "Recommendation: Osteoporosis to Prevent Fractures: Screening | United States Preventive Services Taskforce",
      "url": "https://www.uspreventiveservicestaskforce.org/uspstf/index.php/recommendation/osteoporosis-screening"
    },
    {
      "title": "Summary of main recommendations | NOGG",
      "url": "https://www.nogg.org.uk/full-guideline/summary-main-recommendations"
    },
    {
      "title": "Recommendations | Osteoporosis: assessing the risk of fragility fracture | Guidance | NICE",
      "url": "https://www.nice.org.uk/guidance/cg146/chapter/Recommendations"
    },
    {
      "title": "Osteoporosis Risk Assessment PDF 66144025463749 | PDF | Osteoporosis | Risk Assessment",
      "url": "https://www.scribd.com/document/1067898832/osteoporosis-risk-assessment-pdf-66144025463749"
    },
    {
      "title": "Calcium/Vitamin D Requirements, Recommended Foods & Supplements",
      "url": "https://www.bonehealthandosteoporosis.org/patients/treatment/calciumvitamin-d/"
    },
    {
      "title": "Section 5: Non-pharmacological management of osteoporosis",
      "url": "https://www.nogg.org.uk/full-guideline/section-5-non-pharmacological-management-osteoporosis"
    },
    {
      "title": "Strong, steady and straight: UK consensus statement on physical activity and exercise for osteoporosis",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9304091/"
    },
    {
      "title": "Exercise for preventing falls in older people living in the community",
      "url": "https://www.cochrane.org/evidence/CD012424_exercise-preventing-falls-older-people-living-community"
    },
    {
      "title": "Evidence Summary: Falls Prevention in Community-Dwelling Older Adults: Interventions",
      "url": "https://www.uspreventiveservicestaskforce.org/uspstf/document/final-evidence-summary/falls-prevention-community-dwelling-older-adults-interventions"
    },
    {
      "title": "Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells",
      "url": "https://pubmed.ncbi.nlm.nih.gov/11792566/"
    },
    {
      "title": "Section 6: Pharmacological treatment options | NOGG",
      "url": "https://www.nogg.org.uk/full-guideline/section-6-pharmacological-treatment-options"
    },
    {
      "title": "Prolia prescribing information",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125320s216lbl.pdf"
    },
    {
      "title": "FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia (denosumab)",
      "url": "https://www.fda.gov/drugs/drug-safety-communications/fda-adds-boxed-warning-increased-risk-severe-hypocalcemia-patients-advanced-chronic-kidney-disease"
    },
    {
      "title": "DailyMed - FORTEO- teriparatide injection, solution",
      "url": "https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=aae667c5-381f-4f92-93df-2ed6158d07b0"
    },
    {
      "title": "TYMLOS (abaloparatide) prescribing information",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208743s017lbl.pdf"
    },
    {
      "title": "DailyMed - EVENITY- romosozumab-aqqg injection, solution",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=471baba2-7154-4488-9891-0db2f46791e7"
    },
    {
      "title": "Denosumab and Teriparatide Transitions in Postmenopausal Osteoporosis (The DATA-Switch Study): a Randomised Controlled Trial",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4620731/"
    },
    {
      "title": "Pharmacological Management of Osteoporosis in Postmenopausal Women Guideline Resources | Endocrine Society",
      "url": "https://www.endocrine.org/clinical-practice-guidelines/osteoporosis-in-postmenopausal-women"
    },
    {
      "title": "Evidence-Based Guideline for the management of osteoporosis in men",
      "url": "https://www.esceo.org/sites/esceo/files/pdf/Evidence-based%20guideline%20for%20the%20management%20of%20osteoporosis%20in%20men_Fuggle%20et%20al.pdf"
    },
    {
      "title": "Study of bone mass with dual energy x-ray absorptiometry in a population of 99 lower limb amputees",
      "url": "https://pubmed.ncbi.nlm.nih.gov/12657478/"
    },
    {
      "title": "BMD and bone geometry in transtibial and transfemoral amputees",
      "url": "https://pubmed.ncbi.nlm.nih.gov/18410229/"
    },
    {
      "title": "Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update",
      "url": "https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2017-CKD-MBD-GL-Update-Synopsis.pdf"
    },
    {
      "title": "Measurement of bone mineral in vivo: an improved method. 1963.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/19287886/"
    },
    {
      "title": "Bone Radionuclide Imaging, Quantitation and Bone Densitometry",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK500203/"
    },
    {
      "title": "Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/7941614/"
    },
    {
      "title": "The diagnosis of osteoporosis",
      "url": "https://pubmed.ncbi.nlm.nih.gov/7976495/"
    },
    {
      "title": "Assessing the Risk of Bone Disease and Fracture",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK45525/"
    },
    {
      "title": "History of alendronate",
      "url": "https://pubmed.ncbi.nlm.nih.gov/32437874/"
    },
    {
      "title": "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group",
      "url": "https://pubmed.ncbi.nlm.nih.gov/8950879/"
    },
    {
      "title": "Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis",
      "url": "https://pubmed.ncbi.nlm.nih.gov/11346808/"
    },
    {
      "title": "Osteoporosis: Prevention and Treatment",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK279073/"
    },
    {
      "title": "FDA-Approved Pharmacologic Agents for the Prevention or Treatment of Osteoporosis Included in this Review",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK611362/table/appa.tab3/?report=objectonly"
    },
    {
      "title": "SCOPE 2021: a new scorecard for osteoporosis in Europe",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/8172408/"
    },
    {
      "title": "Key statistic for Europe",
      "url": "https://www.osteoporosis.foundation/facts-statistics/key-statistic-for-europe"
    },
    {
      "title": "Cost-effectiveness of orthogeriatric and fracture liaison service models of care for hip fracture patients: a population based study",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5321497/"
    },
    {
      "title": "A fracture liaison service for patients with osteoporotic fractures.",
      "url": "https://pubmed.ncbi.nlm.nih.gov/14737805/"
    },
    {
      "title": "Section 9: Models of care for fracture prevention",
      "url": "https://www.nogg.org.uk/full-guideline/section-9-models-care-fracture-prevention"
    },
    {
      "title": "Overview: Osteoporosis: assessing the risk of fragility fracture",
      "url": "https://www.nice.org.uk/Guidance/cg146"
    },
    {
      "title": "3 Committee discussion: Bisphosphonates for treating osteoporosis",
      "url": "https://www.nice.org.uk/guidance/ta464/chapter/3-Committee-discussion"
    },
    {
      "title": "AACE/ACE 2020 Postmenopausal Osteoporosis Treatment Algorithm",
      "url": "https://pro.aace.com/pdfs/AACE_Postmenopausal_Osteoporosis_Treatment_Algorithm_Update_022020.pdf"
    },
    {
      "title": "Barriers and solutions for global access to osteoporosis management: a Position Paper from the International Osteoporosis Foundation",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12460584/"
    },
    {
      "title": "Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research (2016)",
      "url": "https://www.asbmr.org/about/task-force-reports-detail/managing-osteoporosis-in-patients-on-long-term-bis"
    },
    {
      "title": "FRAX: Identifying People at High Risk of Fractures",
      "url": "https://www.osteoporosis.foundation/sites/iofbonehealth/files/2020-04/FRAX-Identifying-People-At-High-Risk-of-Fractures.pdf"
    },
    {
      "title": "Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8609461/"
    },
    {
      "title": "Efficacy and Safety of Single Dose Zoledronic Acid for Osteoporosis in Frail Seniors: A Randomized Clinical Trial",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4843134/"
    },
    {
      "title": "Advancing osteoporosis opportunistic screening: multicenter validation of a deep learning algorithm using abdominal CT scans",
      "url": "https://pubmed.ncbi.nlm.nih.gov/41171405/?dopt=Abstract"
    }
  ],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}